RiverFront Investment Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

RiverFront Investment Group’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-38,919	Closed	-$896K	–	134
2023 Q4	$896K	Sell	38,919 -2,127	-5%	-$42.7K	0.03%	86
2023 Q3	$835K	Sell	41,046 -1,408	-3%	-$31.6K	0.03%	84
2023 Q2	$991K	Sell	42,454 -1,190	-3%	-$28.5K	0.03%	82
2023 Q1	$1.02M	Sell	43,644 -1,958	-4%	-$49K	0.04%	79
2022 Q4	$1.15M	Buy	45,602 +22,334	+96%	+$600K	0.26%	68
2022 Q3	$614K	Sell	23,268 -1,057	-4%	-$32.6K	0.02%	74
2022 Q2	$703K	Sell	24,325 -69	-0.3%	-$2.06K	0.03%	77
2022 Q1	$840K	Buy	24,394 +11,552	+90%	+$408K	0.03%	77
2021 Q4	$563K	Buy	+12,842	New	+$608K	0.02%	79

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

RiverFront Investment Group's IDNA Position: Q1 2024 in Review

RiverFront Investment Group sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q1 2024, closing a stake of 38,919 shares — an estimated $896K sold.

RiverFront Investment Group first reported a position in IDNA in Q4 2021 and held it in 9 quarters. The position peaked at $1.15M in Q4 2022. 63 funds tracked by Wall St. Rank hold IDNA as of Q1 2024.

RiverFront Investment Group reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q1 2024 after selling out during the quarter.
RiverFront Investment Group sold 38,919 iShares Genomics Immunology and Healthcare ETF shares in Q1 2024, an estimated $896K.
RiverFront Investment Group first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2021 and held it in 9 quarters.
RiverFront Investment Group's iShares Genomics Immunology and Healthcare ETF position peaked at $1.15M in Q4 2022.
63 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q1 2024.

Based on RiverFront Investment Group's 13F filing for Q1 2024, filed 2 May 2024.